ORIGINAL RESEARCH

Toll-like Receptor 9 Promotes Initiation of Gastric Tumorigenesis by Augmenting Inflammation and Cellular Proliferation

Ke Tang,1,2 Louise McLeod,1,2 Thaleia Livis,1,2 Alison C. West,1,2 Ruby Dawson,1,2 Liang Yu,1,2 Jesse J. Balic,1,2 Michelle Chonwerawong,1,2 Georgie Wray-McCann,1,2 Hiroko Oshima,3 Masanobu Oshima,3 Virginie Deswaerte,1,2 Richard L. Ferrero,1,2,4 and Brendan J. Jenkins1,2

1Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Victoria, Australia; 2Department of Molecular Translational Science, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria, Australia; 3Division of Genetics, Cancer Research Institute, Kanazawa University, Kanazawa, Japan; and 4Biomedicine Discovery Institute, Department of Microbiology, Monash University, Clayton, Victoria, Australia

SUMMARY

We reveal that the innate immune toll-like receptor 9 (TLR9) promotes the initiating stages of gastric carcinogenesis, including that triggered by Helicobacter pylori infection. These findings provide in vivo evidence for TLR9 as a candidate therapeutic target in gastric cancer.

BACKGROUND & AIMS: Gastric cancer (GC) is strongly linked with chronic gastritis after Helicobacter pylori infection. Toll-like receptors (TLRs) are key innate immune pathogenic sensors that mediate chronic inflammatory and oncogenic responses. Here, we investigated the role of TLR9 in the pathogenesis of GC, including Helicobacter infection.

METHODS: TLR9 gene expression was profiled in gastric tissues from GC and gastritis patients and from the spontaneous gp130−/− mouse model and chronic H. felis-infected wild-type (WT) mice. Gastric pathology was compared in gp130−/− and H. felis infection models with or without genetic ablation of Tlr9. The impact of Tlr9 targeting on signaling cascades implicated in inflammation and tumorigenesis (eg, nuclear factor kappa B, extracellular signal-related kinase, and mitogen-activated protein kinase) was assessed in vivo. A direct growth-potentiating effect of TLR9 ligand stimulation on human GC cell lines and gp130−/− primary gastric epithelial cells was also evaluated.

RESULTS: TLR9 expression was up-regulated in Helicobacter-infected gastric tissues from GC and gastritis patients and gp130−/− and H. felis-infected WT mice. Tlr9 ablation suppressed initiation of tumorigenesis in gp130−/−/Tlr9−/− mice by abrogating gastric inflammation and cellular proliferation. Tlr9−/− mice were also protected against H. felis-induced gastric inflammation and hyperplasia. The suppressed gastric pathology upon Tlr9 ablation in both mouse models associated with attenuated nuclear factor kappa B and, to a lesser extent, extracellular signal-related kinase, mitogen-activated protein kinase signaling. TLR9 ligand stimulation of human GC cells and gp130−/− GECs augmented their proliferation and viability.

CONCLUSIONS: Our data reveal that TLR9 promotes the initiating stages of GC and facilitates Helicobacter-induced gastric inflammation and hyperplasia, thus providing in vivo evidence for TLR9 as a candidate therapeutic target in GC. (Cell Mol Gastroenterol Hepatol 2022; https://doi.org/10.1016/j.jcmgh.2022.06.002)

Keywords: Gastric Cancer; Initiation; H. pylori; TLR9.

Gastric cancer (GC) is the third most lethal cancer worldwide, with 5-year relative survival rates lower than 25% because of the late diagnosis and limited effectiveness of current treatments.2 The major histopathologic type of human GC is intestinal-type adenocarcinoma, which develops stepwise from superficial gastritis (ie, gastric inflammation), atrophic gastritis, intestinal metaplasia, and dysplasia.3 GC is also divided into cardia and non-cardia topographical subsites in the stomach, the latter of which has a higher frequency and is associated with infection by Helicobacter pylori, a Gram-negative bacterial pathogen that accounts for ~6% of the global cancer burden.1,5

The strong association between H. pylori-induced gastritis and GC implicates host immune regulators with pro-tumorigenic activities, albeit currently ill-defined, in promoting the molecular pathogenesis of GC. In this respect, H. pylori exerts its pathogenicity through interactions with the host mucosal immune system, in which innate immune toll-like receptors (TLRs) play a vital role in recognizing diverse ligands of microbial and host origins to orchestrate the ensuing inflammatory response.5,7 Over recent years, it has emerged that TLRs may also contribute to the pathogenesis of human malignancies, including GC, via the regulation of epithelial cell proliferation, apoptosis,

Abbreviations used in this paper: ANOVA, analysis of variance; ERK, extracellular signal-related kinase; GC, gastric cancer; MAPK, mitogen-activated protein kinase; NF-κB, nuclear factor kappa B; PCNA, proliferating cell nuclear antigen; PI3K, phosphatidylinositol-3-kinase; qPCR, quantitative polymerase chain reaction; TCGA, The Cancer Genome Atlas; TLR, toll-like receptor; TME, tumor microenvironment; WT, wild-type.

© 2022 The Authors. Published by Elsevier Inc. on behalf of the AGA Institute. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
epithelial-mesenchymal transition, angiogenesis, metastasis, and immunosuppression through multiple signaling pathways. These oncogenic TLR-driven reponses are transduced via numerous signaling cascades, such as nuclear factor kappa B (NF-κB), extracellular signal-related kinase (ERK) mitogen-activated protein kinase (MAPK), and phosphatidylinositol 3-kinase (PI3K)/Akt.\(^\text{1}\text{,2}\text{,3}\) Along with the high degree of genetic and molecular heterogenicity in human GC, together with study design differences based on patient characteristics (e.g., geographical location, ethnicity, age, tumor stage, histologic grade, anatomic location).\(^\text{4}\text{,5}\) With respect to TLR2, its up-regulated expression in tumors from GC patients is associated with poor survival outcomes, and using the \(\text{gp130}^{F/F}\) spontaneous mouse model for intestinal-type GC, along with human GC xenographs, we have demonstrated that the up-regulation of TLR2 in gastric epithelial (tumor) cells promotes tumorigenesis in a tumor cell intrinsic manner (i.e., independent of tumor inflammation).\(^\text{6}\text{,7}\) Despite these observations, a causal role for other TLRs in the molecular pathogenesis of GC remains ill-defined.

TLR9 is an endosomal sensor of unmethylated CpG-rich DNA motifs and is up-regulated in numerous human cancers affecting the lung, pancreas, breast, esophagus, nasopharynx, and brain, as well as in \(H.\) pylori-positive GC.\(^\text{8}\text{,9}\text{,10}\text{,11}\) Numerous in vitro and in vivo studies have shown that TLR9 promotes distinct pro-tumorigenic effects in immune and non-immune cells, including angiogenesis, immunosuppression, cell proliferation, and invasion.\(^\text{12}\text{,13}\text{,14}\) Conversely, TLR9 agonists can also trigger anti-tumor immunity in some cancer types (e.g., lung, colon).\(^\text{15}\text{,16}\text{,17}\) Indeed, the complex and contrasting contribution of TLR9 signaling to carcinogenesis also extends to gastric inflammation in vivo models induced by \(H.\) pylori infection (3–6 weeks), whereby acute host immune responses are either suppressed (neutrophil infiltrates, interferon γ production) or augmented (interleukin 17 production) in infected Tlr9\(^{-/-}\) mice.\(^\text{18}\text{,19}\text{,20}\)

To provide definitive insights into the mechanistic role of TLR9 in inflammation-associated GC, here we show that TLR9 expression was elevated in both uninfected \(\text{gp130}^{F/F}\) and chronic (4-month) \(H.\) pylori-infected wild-type (WT) mice, as well as in clinical biopsies from GC and \(H.\) pylori-infected gastritis patients. Furthermore, by coupling Tlr9\(^{-/-}\) mice with uninfected \(\text{gp130}^{F/F}\) mice, we reveal that the genetic ablation of Tlr9 suppressed the onset of gastric tumorigenesis, which was accompanied by reduced gastric mucosal inflammation and cellular proliferation. Similarly, \(H.\) felis-induced gastric inflammation and epithelial hyperplasia were ameliorated in Tlr9\(^{-/-}\) mice. Collectively, our findings demonstrate that activation of TLR9 signaling promotes gastric tumorigenesis in the initiating stage, at least in part, by augmenting inflammation and cellular proliferation.

### Results

#### TLR9 Expression Is Augmented in Early-Stage Gastric Tumors of Gastric Cancer Patients and Correlates With Impaired Survival

In 2 independent GC patient cohorts, the Cancer Genome Atlas (TCGA) and an Australian-based mixed Caucasian/Asian cohort, TLR9 mRNA levels were significantly up-regulated in 78% (14/18) and 65% (13/20) of gastric tumor tissues, respectively, compared with matched adjacent non-tumor tissues (Figure 1A–D, Table 1). Among all TLR family members, only TLR9 along with TLR2 were significantly up-regulated in gastric tumor tissues from GC patients; the latter observation for TLR2 is consistent with our previous report.\(^\text{16}\) (Figure 1A). Interestingly, in the large Genetic Cancer Project ‘08 – Singapore Patient Cohort comprising tumor only samples (Table 1),\(^\text{21}\) the segregation of GC patient primary tumors into either low or high TLR9 gene expression revealed that high TLR9 levels were prognostic for impaired overall >10-year survival, with patients expressing high versus low TLR9 mRNA levels having a median survival of 31.2 versus 56.9 months (Figure 1E). We also note that the stratification of GC patients by disease stage showed that among TLRs, only TLR9 mRNA expression levels were significantly elevated in early-stage I and II patients compared with advanced-stage III and IV patients (Figure 1F). Collectively, these data indicate that augmented TLR9 expression is a feature of early-stage human GC.

#### Genetic Targeting of TLR9 in the gp130\(^{F/F}\) Gastric Cancer Mouse Model Suppresses Tumor Initiation, but not Progression

We next assessed the expression of Tlr9 by quantitative polymerase chain reaction (qPCR) in the preclinical \(\text{gp130}^{F/F}\) GC mouse model, which from 6 weeks of age onward spontaneously develops antral gastric intestinal-type tumors (with 100% penetrance) that progress in size until a maximal growth is reached at 24–26 weeks of age.\(^\text{22}\text{,23}\) Although gastric Tlr9 mRNA levels were unchanged in pre-tumorigenic 4-week-old \(\text{gp130}^{F/F}\) mice, Tlr9 gene expression was significantly elevated (2- to 3-fold) at 12 weeks of age in \(\text{gp130}^{F/F}\) gastric antral tumors compared with either adjacent non-tumor antral tissue or normal antral tissues of \(\text{gp130}^{-/-}\) (WT) mice (Figure 2A). Notably, laser microdissection coupled with qPCR on gastric tissues from tumor-bearing \(\text{gp130}^{F/F}\) versus tumor-free WT mice indicated that Tlr9 mRNA levels were elevated in the epithelium (enriched for \(\text{EpCam}\) gene expression) versus immune cell-containing stroma (enriched for \(\text{Ptprc}\) (CD45) gene expression) within each gastric tissue genotype, with highest Tlr9 gene expression observed in the \(\text{gp130}^{F/F}\) tumor epithelium (Figure 2B). In support of these observations, Tlr9 mRNA levels were also significantly higher in primary gastric epithelial cells derived from \(\text{gp130}^{F/F}\) versus WT mice (Figure 2C). Conversely, at 24 weeks of age Tlr9 mRNA levels were significantly elevated (2- to 3-fold) in \(\text{gp130}^{F/F}\) non-tumor antral tissue compared with both
gp130/F/F gastric antral tumors and WT antral tissues (Figure 2A).

To define whether a causal relationship exists between increased gastric tumoral expression of TLR9 and the pathogenesis of GC, we generated TLR9-deficient gp130/F/F mice (gp130/F/F;Tlr9/−). By 10 weeks of age (early-stage tumorigenesis), the stomachs and gastric tumors of gp130/F/F;Tlr9/− mice were visibly smaller and significantly
redistributed in weight (49% and 62%, respectively) compared with age-matched gp130<sup>F/F</sup> littermates (Figure 2D–F). Surprisingly, however, suppressed gastric tumorigenesis was not apparent in 20-week-old and 30-week-old gp130<sup>F/F</sup>:Tlr9<sup>−/−</sup> mice, in which both stomach size and gastric tumor burden were comparable with age-matched gp130<sup>F/F</sup> mice (Figure 2G–L). We note that tumor incidence was similar between the genotypes at each age group (Figure 2M). Therefore, genetic ablation of TLR9 in the gp130<sup>F/F</sup> GC model preferentially inhibits the early initiation of disease (tumor) stage. *<sup>P</sup> < 0.05; unpaired two-way ANOVA. (E) Expression of TLR9 in gastric tissue sections normalized to matched non-tumor tissues in the patient cohort from (A). *<sup>P</sup> < 0.05, paired Student t test. (C and D) Expression of TLR9 in (C) gastric tumors and matched, adjacent non-tumor tissues and (D) gastric tumor tissues normalized to matched non-tumor tissues in TCGA intestinal-type GC patients (n = 18). *<sup>P</sup> < 0.05; unpaired (C) and paired (D) Student t tests. (E) Kaplan–Meier 10-year survival analysis of the Gastric Cancer Project –08 - Singapore Patient Cohort (n = 129) stratified into 2 groups based on low (dashed line) or high (solid line) TLR9 gene expression. Also shown is the median survival (months). Log-rank (Mantel-Cox) test. (F) Scatter plot showing TLR9 mRNA expression levels in tumor tissues from intestinal-type GC patients belonging to the Gastric Cancer Project –08 - Singapore Patient Cohort (n = 160) stratified by disease (tumor) stage. *<sup>P</sup> < 0.05; one-way ANOVA.

Table 1. Clinicopathologic Features and Demographics of the Gastric Cancer Patient Cohorts Used for TLR9 Expression Profiling

| TCGA | Australian | Singapore<sup>a</sup> |
|------|------------|-----------------------|
| Mean age | 66 (50–81) | 61.5 (35–84) | 68.05 (25–89) |
| Years (range) | | | |
| Sex, n (%) | | | |
| Male | 15 (83.3) | 13 (65) | 101 (63) |
| Female | 3 (16.7) | 7 (35) | 50 (31) |
| Unknown | 0 (0) | 0 (0) | 9 (6) |
| Histologic type, n (%) | | | |
| Intestinal-type | 18 (100) | 16 (80) | 90 (56) |
| Diffuse | 0 (0) | 4 (20) | 70 (44) |
| H<sub>p</sub>/<sub>i</sub> status, n (%) | | | |
| Positive | 1 (5.6) | 7 (35) | 44 (28) |
| Negative | 4 (22.2) | 13 (65) | 34 (21) |
| Unknown | 13 (72.2) | 0 (0) | 82 (51) |
| Tumor grade, n (%) | | | |
| 1 | 2 (11.1) | 2 (10) | 12 (8) |
| 2 | 12 (66.7) | 8 (40) | 27 (17) |
| 3 | 4 (22.2) | 9 (45) | 83 (52) |
| 4 | 0 (0) | 1 (5) | 38 (23) |

TCGA, The Cancer Genome Atlas.

<sup>a</sup>Gastric Cancer Project –08 - Singapore Patient Cohort (GSE15459).

Suppressed Early-Stage Gastric Tumorigenesis in gp130<sup>F/F</sup>:Tlr9<sup>−/−</sup> Mice Is Associated With Reduced Gastric Inflammation and Cellular Proliferation

We next evaluated whether the suppressed early GC phenotype of gp130<sup>F/F</sup>:Tlr9<sup>−/−</sup> mice coincided with reduced tumor-associated inflammation. Indeed, histologic assessment of H&E-stained gastric tissue sections from 10-week-old mice indicated that the inflammation score (chronic inflammatory cell infiltrates in the submucosa and mucosa) in gp130<sup>F/F</sup>:Tlr9<sup>−/−</sup> gastric tumors was significantly lower compared with age-matched gp130<sup>F/F</sup> tumors (Figure 3A). Immunohistochemical analyses also indicated significantly lower numbers of infiltrating CD4<sup>+</sup> lymphocytes, B220<sup>+</sup> B cells, and CD3<sup>+</sup> T cells in the gastric mucosa of 10-week-old gp130<sup>F/F</sup>:Tlr9<sup>−/−</sup> versus gp130<sup>F/F</sup> mice (Figure 3B–D). The reduced gastric inflammation in smaller gp130<sup>F/F</sup>:Tlr9<sup>−/−</sup> tumors was also confirmed at the molecular level, as evidenced by significantly lower mRNA levels of inflammatory genes (Tnfa, Cxcl1, Cxcl2) and protein levels of tumor necrosis factor α in 10-week-old gp130<sup>F/F</sup>:Tlr9<sup>−/−</sup> versus gp130<sup>F/F</sup> gastric tumors (Figure 3E and F). By contrast, the expression of several angiogenesis-related genes (Mmp2, Mmp9, Vegf) was comparable in gastric tumors of gp130<sup>F/F</sup>:Tlr9<sup>−/−</sup> and gp130<sup>F/F</sup> mice, suggesting that TLR9 does not promote angiogenesis in the early
**TLR9 Initiates Gastric Tumorigenesis**

- **Figure A**: Relative expression of Tlr9 in WT and F/F mice at 4wo, 12wo, and 24wo.
- **Figure B**: Relative expression of EpCam and Ptprc in F/F and WT mice at 10wo.
- **Figure C**: Relative expression of PGECs in WT and F/F mice.
- **Figure D**: Stomach mass (g) in F/F and F:F:Tlr9-/- mice at 10wo.
- **Figure E**: Tumor incidence in WT and F/F mice at 20wo.
- **Figure F**: Tumor incidence in WT and F/F mice at 30wo.

---

**Additional Tables and Figures**

- Table 1: Relative expression of Tlr9, EpCam, and Ptprc in different genotypes.
- Figure 2: Comparison of stomach mass and tumor mass (g) between WT and F/F mice.
- Figure 3: Tumor incidence in F/F and F:F:Tlr9-/- mice at different time points.

---

**References**

1. FLA 5.6.0 DTD
2. JCMGH1031 proof
3. 30 June 2022
4. 12:13 pm
5. ce CLR
establishment stage of gastric tumorigenesis (Figure 3G). Consistent with the comparable gastric tumorigenesis in older (20-week-old) gp130\textsuperscript{+/}Tlr9\textsuperscript{-/-} and gp130\textsuperscript{+/}F/F mice, similar levels of gastric inflammation were observed in tumors of aged gp130\textsuperscript{+/}F/F,Tlr9\textsuperscript{-/-} and gp130\textsuperscript{+/}F/F mice (Figure 3H–K). We also note a previous report that aberrant activation of M2-type macrophages can be associated with gastric tumor growth in mice.\textsuperscript{29} Consistent with this, we observed transcriptional up-regulation of M2-type markers (Arg1, Egr2), but not M1-type markers (Cd38, Gpr18), in gp130\textsuperscript{+/}F/F gastric tumors (Figure 3L). However, TLR9 deficiency in gp130\textsuperscript{+/}F/F,Tlr9\textsuperscript{-/-} mice did not alter the gastric expression profile of these M2-type macrophage markers, suggesting TLR9 promotes gastric inflammation and tumorigenesis independent of M2-type macrophage activation (Figure 3L).

Because elevated gastric epithelial cell proliferation and survival are prominent features of early-stage gastric tumorigenesis in gp130\textsuperscript{+/}F/F mice,\textsuperscript{25} we next investigated whether TLR9 promoted these oncogenic cellular processes in 10-week-old gp130\textsuperscript{+/}F/F mice. Indeed, immunohistochemistry indicated that proliferating cell nuclear antigen (PCNA)\textsuperscript{-} proliferating cell numbers were significantly decreased (~40%) in the epithelium of gastric tumors of gp130\textsuperscript{+/}F/F,Tlr9\textsuperscript{-/-} compared with gp130\textsuperscript{+/}F/F mice (Figure 4A). These observations were also supported at the molecular level, whereby the expression of a series of proliferative genes (Bcl2a1, Ccnb1, Ccnd1, Myc) was significantly reduced in gastric tumors from 10-week-old gp130\textsuperscript{+/}F/F,Tlr9\textsuperscript{-/-} mice compared with their age-matched gp130\textsuperscript{+/}F/F control mice (Figure 4B). By contrast, with respect to cell survival, apoptotic cleaved Caspase-3\textsuperscript{+} or TUNEL\textsuperscript{+} cell numbers in 10-week-old gp130\textsuperscript{+/}F/F,Tlr9\textsuperscript{-/-} and gp130\textsuperscript{+/}F/F gastric tumors were comparable (Figure 4C and D). Notably, similar levels of cellular proliferation and apoptosis and proliferative gene expression were observed in tumors of aged (20-week-old) gp130\textsuperscript{+/}F/F,Tlr9\textsuperscript{-/-} and gp130\textsuperscript{+/}F/F mice (Figure 4E–G). Collectively, these data indicate that TLR9 selectively promotes cellular proliferation and inflammation during the early establishment of gastric tumors in the gp130\textsuperscript{+/}F/F GC mouse model.

Suppressed Early-Stage Gastric Tumorigenesis in gp130\textsuperscript{+/}F/F,Tlr9\textsuperscript{-/-} Mice Is Associated With Reduced Activation of Nuclear Factor Kappa B and Extracellular Signal-Related Kinase Mitogen-Activated Protein Kinase Signaling Cascades

To identify TLR9-dependent signaling pathways associated with early-stage gastric tumorigenesis in 10-week-old gp130\textsuperscript{+/}F/F mice, we performed Western blots to evaluate the activation (phosphorylation) of NF-κB, ERK1/2, MAPK, PI3K/Akt, and STAT3 pathways. The protein levels of phosphorylated (p) NF-κB p65 and pERK1/2 were significantly lower (42% and 20%, respectively) in gastric tumors of 10-week-old gp130\textsuperscript{+/}F/F,Tlr9\textsuperscript{-/-} compared with gp130\textsuperscript{+/}F/F mice, whereas levels of pAkt and pSTAT3 were comparable between these 2 genotypes (Figure 5A–D). We further verified that reduced tumorigenesis in gp130\textsuperscript{+/}F/F,Tlr9\textsuperscript{-/-} mice was not a consequence of altered STAT3 signaling, as evidenced by comparable mRNA expression levels of STAT3-target genes (Socs3, Il11) in tumors of 10-week-old gp130\textsuperscript{+/}F/F,Tlr9\textsuperscript{-/-} and gp130\textsuperscript{+/}F/F mice (Figure 5E). Immunohistochemical analyses also confirmed decreased pNF-κB p65\textsuperscript{+} and pERK1/2\textsuperscript{+} cell numbers in gastric tumors, predominantly the glandular epithelium, of 10-week-old gp130\textsuperscript{+/}F/F,Tlr9\textsuperscript{-/-} versus gp130\textsuperscript{+/}F/F mice, with the reduction again more pronounced for pNF-κB p65 (45%) than pERK1/2 (30%) (Figure 5F and G). By contrast, at 20 weeks of age, expression levels of pNF-κB p65 (very low) and pERK1/2 were comparable in tumors between gp130\textsuperscript{+/}F/F,Tlr9\textsuperscript{-/-} versus gp130\textsuperscript{+/}F/F mice (Figure 5H and I), suggesting that TLR9 does not engage these pathways in later stages of tumorigenesis. Taken together, these data support the notion that genetic targeting of TLR9 inhibits early-stage gastric tumorigenesis in 10-week-old gp130\textsuperscript{+/}F/F mice.

Figure 2. (See previous page). TLR9 promotes gastric tumorigenesis in 10-week-old gp130\textsuperscript{+/}F/F mice. (A) Tlr9 expression by qPCR (after normalization for 18S rRNA) in the indicated gastric antral tissues from 4-week-old, 12-week-old, and 24-week-old gp130\textsuperscript{+/}F/F (WT) and gp130\textsuperscript{+/}F/F (F/F) mice. NT, non-tumor; T, tumor; n = 6 mice/genotype. *P < .05, **P < .01; unpaired Student t tests. (B) qPCR expression analyses of Tlr9, EpCam, and Ptprc (after normalization for 18S rRNA) in captured laser microdissected gastric epithelial (Epi) and stroma (Str) tissue from WT and/or tumor-bearing F/F mice. n = 4 samples/genotype. *P < .05, **P < .01; one-way ANOVA for Tlr9, and paired Student t test for EpCam and Prp. (C) qPCR of Tlr9 (after normalization for 18S rRNA) in primary gastric epithelial cells (PGECs) from WT and F/F mice. n = 4 samples/genotype. *P < .05; unpaired Student t test. (D) Representative (D) photomicrographs showing H&E-stained whole scan and (E) macroscopic appearance, of stomachs from 10-week-old F/F and F/F,Tlr9\textsuperscript{-/-} mice. In (D), tumors are depicted by dotted squares. Scale bars: 1 cm. In (E), arrows indicate macroscopically visible tumors. Fundus (f), body (b), and antral (a) stomach areas are labeled. Scale bars: 1 cm. (F) Graphs depicting the total mass (g) of stomachs and gastric tumors of 10-week-old F/F and F/F,Tlr9\textsuperscript{-/-} mice. n = 12 mice/genotype. ****P < .0001; unpaired Student t tests. (G and H) Representative (G) photomicrographs showing H&E-stained whole scan and (H) macroscopic appearance of stomachs from 20-week-old F/F and F/F,Tlr9\textsuperscript{-/-} mice. In (G), tumors are depicted by dotted squares. Scale bars: 1 cm. In (H), arrows indicate macroscopically visible tumors. Scale bars: 1 cm. (I) Graphs depicting the total mass (g) of stomachs and gastric tumors of 20-week-old F/F and F/F,Tlr9\textsuperscript{-/-} mice. n = 12 mice/genotype. (J and K) Representative (J) photomicrographs showing H&E-stained whole scan and (K) macroscopic appearance of stomachs from 30-week-old F/F and F/F,Tlr9\textsuperscript{-/-} mice. In (J), tumors are depicted by dotted squares. Scale bars: 1 mm. In (K), arrows indicate macroscopically visible tumors. Scale bars: 1 cm. (L) Graphs depicting the total mass (g) of stomachs and gastric tumors of 30-week-old F/F and F/F,Tlr9\textsuperscript{-/-} mice. n = 12 mice/genotype. (M) Graphs depicting total tumor incidence by size in the indicated 10-week-old, 20-week-old, and 30-week-old F/F and F/F,Tlr9\textsuperscript{-/-} mice. n = 12 mice/genotype.
mice, at least in part, through suppressed activation of NF-κB and ERK pathways, but not via PI3K/Akt or STAT3 pathways.

**Increased TLR9 Expression in Human and Mouse Gastric Epithelial (Cancer) Cells Enhances TLR9 Ligand-Driven Cell Growth**

Because of the recent emergence that TLR family members (ie, TLR2) can exert pro-tumorigenic effects by directly acting on GC cells to augment their cellular proliferation and survival,7,9,11 we investigated whether ligand-induced activation of TLR9 could directly enhance the growth responsiveness of human GC cell lines. For this purpose, we used qPCR and Western blotting to stratify a panel of 9 human GC cell lines, along with a control human duodenal cancer cell line (AZ521), into either TLR9 low-expressing (TLR9low) (N87, SN116, TMK1, AGS, MNK7) and TLR9 high-expressing (TLR9high) (SNU601, MKN1, MKN28, NUGC4) cell lines (Figure 6A–C, Table 2). We next stratified representative TLR9high NUGC4 and MKN28 cell lines, along with the TLR9low AGS cell line as a control, with the TLR9 agonist CpG DNA to measure cell proliferation and cell viability. As shown in Figure 6D and E, both cellular proliferation and viability of TLR9high NUGC4 and MKN28 cell lines were significantly enhanced on TLR9 ligand stimulation, whereas TLR9low AGS cells were non-responsive. The capacity of TLR9 activation to augment the proliferation of gastric (epithelial) cancer cells was also confirmed in TLR9 high-expressing primary gastric epithelial cells from the gp130ff GC mouse model, with CpG DNA-stimulated gp130ff epithelial cell cultures displaying a significant increase in proliferation compared with control-treated cultures (Figure 6F–H).

Our in vivo data in the gp130ff model suggest that TLR9 activates NF-κB and, to a lesser extent, ERK MAPK pathways to promote cellular proliferation within the gastric epithelium during tumorigenesis. To further delineate a role for these pathways in transducing TLR9-induced proliferation and viability of gastric epithelial (cancer) cells, we pretreated NUGC4 and MKN28 human GC cells with well-documented inhibitors of the NF-κB (TPCA-1; 1κB kinase-2 inhibitor) and ERK1/2 MAPK (U0126; MAPK kinase inhibitor) pathways before stimulation with CpG DNA. As shown in Figure 6I, treatment with TPCA-1, but not U0126, resulted in a significant inhibition of TLR9 ligand-stimulated cell proliferation and viability. Taken together, these in vitro data demonstrating enhanced TLR9-driven cellular growth are coincident with our in vivo findings in the gp130ff model that TLR9 promotes tumor (epithelial) cell proliferation predominantly via the NF-κB pathway.

**Up-Regulation of TLR9 During Helicobacter Infection Exacerbates Gastric Hyperplasia and Inflammation in Vivo**

Because *H pylori* infection triggers the initiating pre-neoplastic, chronic gastritis stage of GC,2,3 we next investigated the pathologic role of TLR9 in *Helicobacter*-induced gastric disease. TLR9 gene expression profiling of gastric tumors from GC patients stratified for their *H pylori* status revealed that TLR9 mRNA levels were significantly higher (~1.5- to 2-fold) in *H pylori*-positive patients (TCGA and Australian/Chinese cohorts) compared with the corresponding *H pylori*-negative patients (Figure 7A and B). Similarly, in GC-free individuals, TLR9 gene expression was elevated (~4-fold) in *H pylori*-positive versus *H pylori*-negative gastric tissues (Figure 7C). Notably, TLR9 expression in *H pylori*-negative gastric tissues was unchanged irrespective of the grade of gastritis (Figure 7C), suggesting that increased TLR9 expression in GC-free gastric tissues was specifically associated with *H pylori* infection.

*H felis* strongly colonizes the mouse stomach and induces inflamed, hyperplastic gastric lesions that are similar in pathology to the pre-neoplastic, inflammatory lesions triggered by *H pylori* infection in the human stomach.26 We therefore established a chronic *H felis* infection model in WT mice, which was characterized by significant increases in stomach weight and gastric corpus mucosal thickness, as well as up-regulation (~3-fold) of *Thr* mRNA levels in the gastric body at 4 months after infection, compared with broth control gavaged mice (Figure 7D–G). Notably, *H felis*-infected *Thr*+ mice displayed markedly reduced stomach size and weight (32%) and gastric corpus mucosal thickness (25%), compared with *H felis*-infected WT mice (Figure 7E–G). Western blot analyses on gastric tissue lysates from *H felis*
Figure 4. TLR9 promotes cellular proliferation, but not survival, in tumors of 10-week-old gp130+/F mice. (A, C, and D) Representative photomicrographs showing (A) PCNA-stained, (C) cleaved Caspase-3-stained, and (D) TUNEL-stained cross sections under low power (left images) and high power (right images) magnification in gastric tumors from 10-week-old (wo) gp130+/F (F/F) and F/F:TLR9-/- mice. Scale bars: 100 μm (left images), 25 μm (right images). In (D), arrows point to representative TUNEL-positive stained cells. Also shown are the corresponding graphs depicting quantification of positive cells/high-power field (HPF), n = 6 mice/genotype. ***P < .001; unpaired Student t tests. (E and F) Representative photomicrographs of (E) PCNA-stained and (F) TUNEL-stained cross sections under low power (left images) and high power (right images) magnification of gastric tumors from 20wo F/F and F/F:TLR9-/- mice. Scale bars: 100 μm (left images), 25 μm (right images). In (F), arrows point to representative TUNEL-positive stained cells. Also shown are corresponding graphs depicting positive cells/HPF, n = 6 mice/genotype. (G) qPCR of the indicated cell proliferation genes (all relative to 18s rRNA) in gastric tumors from 20wo F/F and F/F:TLR9-/- mice. n = 6 mice/genotype. *P < .05; unpaired Student t tests.
Figure 5. TLR9 promotes gastric tumorigenesis in 10-week-old gp130<sup>F/F</sup> mice through multiple signaling cascades. (A–D) Western blots of gastric tumor tissue lysates from 10-week-old (wo) gp130<sup>F/F</sup> (F/F) and F/F:Tlr9<sup>−/−</sup> mice with the indicated antibodies. Each lane represents an individual mouse sample. Graphs depict densitometric quantification of relative expression of phosphorylated signaling molecules (ratio of phosphorylated versus total protein) from the corresponding blots on gastric tumor tissue lysates (n = 6 mice/genotype). (E) qPCR of the indicated genes (relative to 18s rRNA) in gastric tumors from 10wo F/F and F/F:Tlr9<sup>−/−</sup> mice. (F and G) Representative high power photomicrographs showing immunohistochemical staining of pNF-κB p65 and pERK1/2 in cross sections of gastric tumors from 10wo F/F and F/F:Tlr9<sup>−/−</sup> mice. Scale bars: 50 μm. Graphs depict the corresponding enumeration of positive cells/high power field (HPF). n = 6 mice/genotype. *P < .05, **P < .01; unpaired Student t test. (H) Western blots of gastric tumor tissue lysates from 20wo F/F and F/F:Tlr9<sup>−/−</sup> mice with the indicated antibodies. Each lane represents an individual mouse sample. (I) Graphs depict densitometric quantification of the relative expression of phosphorylated signaling molecules (ratio of phosphorylated versus total protein) from the corresponding blots on gastric tumor tissue lysates (n = 5 mice/genotype).

and broth gavaged WT and Tlr9<sup>−/−</sup> mice showed that protein levels of pNF-κB p65 and pERK1/2 MAPK were significantly higher in the gastric mucosa of H felis-infected WT mice than H felis-infected Tlr9<sup>−/−</sup> mice, the latter of which were similar to WT and Tlr9<sup>−/−</sup> broth control animals (Figure 7H). Therefore, these data suggest that TLR9-dependent NF-κB and ERK1/2 MAPK signaling pathways contribute to H felis-induced gastric pathogenesis in vivo.
Figure 6. TLR9 promotes human GC and mouse gp130<sup>Fl/fl</sup> primary gastric epithelial cell growth in vitro. (A) qPCR expression analyses of TLR9 (normalized to the housekeeping gene ACTB) in human GC cell lines (black bars) and a control duodenal cancer cell line (white bar). Expression values were relative to AGS (assigned a value of “1”), and cell lines with a relative expression value above 1 were defined as high expressing for TLR9, as depicted by the dotted line. (B) Western blots of lysates from human GC cell lines with the indicated antibodies. (C) Densitometry quantification of TLR9 protein expression from (B) relative to tubulin. (D and E) Cell proliferation (D) and viability (E) assays of AGS (TLR9<sup>Low</sup>), NUGC4 (TLR9<sup>High</sup>), and MKN28 (TLR9<sup>High</sup>) cells treated with either TLR9 ligand CpG-DNA (ODN-2006) (2 μmol/L) or control oligonucleotide for 24 and 48 hours, respectively. Data are presented from 3 independent experiments. *P < .05; paired Student t test. (F and G) Representative immunofluorescence images of (F) gp130<sup>Fl/fl</sup> (F/F) primary gastric epithelial cells (GECs) stained for E-cadherin and (G) WT and F/F primary GECs stained for TLR9. DAPI nuclear staining is blue. Scale bars: 50 μm. (H) Proliferation assays of F/F primary GECs treated with either TLR9 ligand CpG-DNA (ODN-2006) (2 μmol/L) or control oligonucleotide for 24 hours. Data are presented from 3 independent experiments. *P < .05; paired Student t test. (I) Cell proliferation and viability assays of NUGC4 cells pretreated with inhibitors of the NF-κB (TPCA-1) and ERK1/2 MAPK (U0126) pathways before stimulation with CpG DNA (2 μmol/L) or control oligonucleotide for 24 and 48 hours, respectively. Data are presented from 3 independent experiments. *P < .05, **P < .001, ***P < .0001; one-way ANOVA.
mice remained slightly higher than those in Tlr9<sup>−/−</sup> control animals, suggesting that TLR9 deficiency led to a partial (albeit significant) reduction in H. felis-induced gastric hyperplasia. These observations were also confirmed at the molecular level on qPCR gene expression analysis of markers for proliferative stem cells (Lgr5), chief cells (Mist1/Blhia15), parietal cells (Atp4a), and metaplasia (Cd44v9). Specifically, consistent with the suppressed gastric proliferative phenotype of Helicobacter-infected Tlr9<sup>−/−</sup> mice (versus WT mice), expression of Lgr5 (increased during Helicobacter infection<sup>26</sup>) was significantly down-regulated (~4.5-fold) in infected Tlr9<sup>−/−</sup> mice compared with WT mice (Figure 8C). With respect to metaplasia (which usually occurs subsequent to gastritis and associated hyperplasia) of chronic Helicobacter infection, gastric Mist1 expression in chief cells, which is suppressed during metaplasia and dysplasia,<sup>30</sup> was similarly down-regulated (5- to 6-fold) in both WT and Tlr9<sup>−/−</sup> mice infected with Helicobacter compared with their broth controls (Figure 8D). Also, Cd44v9 mRNA levels (up-regulated on chronic Helicobacter infection and metaplasia)<sup>23,28</sup> were similarly elevated (2- to 3-fold) in both WT and Tlr9<sup>−/−</sup> mice infected with Helicobacter compared with their broth controls (Figure 8E). Furthermore, consistent with the loss of parietal cells during Helicobacter infection and upon metaplasia,<sup>31</sup> mRNA levels of Atp4a were similarly down-regulated (~4-fold) in WT and Tlr9<sup>−/−</sup> mice infected with Helicobacter compared with their broth controls (Figure 8F). Taken together, these molecular changes further support the notion that TLR9 contributes to early proliferative changes in the gastric mucosa, without impacting on lineage differentiation of gastric epithelial progenitors, during Helicobacter infection.

The reduced gastric hyperplasia in H. felis-infected Tlr9<sup>−/−</sup> mice was associated with lower gastric inflammation, as evidenced by significantly lower inflammation scores and reduced numbers of infiltrating CD45<sup>+</sup>, B220<sup>+</sup>, and CD3<sup>+</sup> immune cell subsets in the stomachs of H. felis-infected Tlr9<sup>−/−</sup> mice compared with their infected WT counterparts (Figure 9A–D). Similarly, at the molecular level, elevated mRNA levels of inflammatory mediators (ie, Cxcl1, Cxcl2, Tnfα) in H. felis-infected WT mouse stomachs (compared with broth control WT) were also significantly lower in infected Tlr9<sup>−/−</sup> mouse stomachs (Figure 9E). Interestingly, the suppressed gastric inflammation (Figure 9A–D) and hyperplasia (Figure 8A and B) in infected Tlr9<sup>−/−</sup> mice occurred despite enhanced H. felis colonization (Figure 9F and G), which is consistent with the inverse relationship between H. pylori colonization and gastritis severity observed in the mouse stomach.<sup>34</sup>

**Discussion**

In this study, we reveal that the TLR9 endosomal DNA sensor promotes early-stage gastric inflammation-associated carcinogenesis. In this respect, our findings are consistent with accumulating evidence for the contribution of TLR9 to the pathogenesis of various cancers (eg, pancreatic cancer, esophageal cancer).<sup>13–17</sup> For example, in

### Table 2. Significance Values Were Calculated for TLR9 Gene Expression (by qPCR) Among TLR9<sup>High</sup> (SNU601, MKN1, MKN28, NUGC4) and TLR9<sup>Low</sup> (N87, SNU16, TMK1, AGS, MKN7) Human Gastric Cancer and Duodenal (AZ521; TLR9<sup>Low</sup>) Cell Lines

| Cell line comparison<sup>a</sup> | P value<sup>b</sup> |
|----------------------------------|------------------|
| AZ521 vs SNU16                   | ****             |
| AZ521 vs MKN7                    | ****             |
| AZ521 vs SNU601                  | ****             |
| MKN1 vs MKN28                    | ****             |
| MKN7 vs NUGC4                    | ****             |
| SNU16 vs MKN1                    | *                |
| N87 vs SNU16                     | ****             |
| N87 vs MKN28                     | ****             |
| MKN7 vs MKN28                    | ****             |
| SNU16 vs MKN28                   | ****             |
| AGS vs SNU601                    | ****             |
| AGS vs MKN1                      | ****             |
| AGS vs NUGC4                     | ****             |
| TMK1 vs AGS                      | ****             |
| TMK1 vs MKN7                     | ****             |
| TMK1 vs SNU601                   | ****             |
| TMK1 vs MKN28                    | ****             |
| TMK1 vs MKN28                    | ****             |
| TMK1 vs NUGC4                    | ****             |
| AGS vs SNU601                    | ****             |
| AGS vs MKN1                      | ****             |
| AGS vs NUGC4                     | ****             |
| MKN7 vs SNU601                   | ****             |
| MKN7 vs MKN28                    | ****             |
| MKN7 vs SNU16                    | ****             |
| MKN7 vs MKN28                    | ****             |
| SNU601 vs MKN1                   | ****             |
| SNU601 vs MKN28                  | ****             |
| MKN1 vs MKN28                    | ****             |
| MKN1 vs NUGC4                    | ****             |

*a* Analyses were performed using one-way ANOVA with Tukey multiple comparison test.

<sup>b</sup>P < .05, ****P < .001, ***P < .0001.
pancreatic cancer, TLR9 has distinct pro-tumorigenic effects on epithelial, immune/inflammatory, and fibroblastic cells, which collectively fuel an inflamed tumor microenvironment (TME) during early disease onset that supports the neoplastic outgrowth of the transformed epithelium.\textsuperscript{13}

Regarding the former, our findings here demonstrate that TLR9 elicits proliferative responses on the gastric epithelium during early-stage tumorigenesis, which is coincident with its transcriptional up-regulation in the gastric (tumor) epithelium, but not immune cell-containing stroma, of 12-week-old (early onset of tumorigenesis) versus 24-week-old (late established tumorigenesis) \textit{gp130\textsuperscript{F/F}} mice. These observations support the notion that in cancers (eg, pancreatic, gastric) whose initiation is reliant on tumor-promoting pro-inflammatory signals, TLR9-driven epithelial (tumor) cell growth, either directly or indirectly via activation of immune cells within the TME, outweights TLR9-mediated adaptive immune-based anti-tumor immunity that

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{TumorInitiation.png}
\caption{TLR9 is up-regulated in human \textit{H pylori}-infected and mouse \textit{H felis}-infected gastric tissues, and \textit{H felis}-induced gastric hyperplasia is suppressed in TLR9-deficient mice. (A and B) Gene expression of TLR9 in gastric tumors from (A) TCGA intestinal-type GC patients (\textit{Hp}+, n = 53; \textit{Hp}−, n = 4), and (B) Australian/Chinese GC patients (\textit{Hp}−, n = 13; \textit{Hp}+, n = 7), based on their \textit{H pylori} (\textit{Hp}) status. *P < .05; unpaired Student t test. (C) qPCR expression of TLR9 (relative to 18S rRNA) in gastric tissues from GC-free individuals, based on the \textit{H pylori} status (\textit{Hp}− normal (N), n = 8; \textit{Hp}− mild gastritis (M), n = 12; \textit{Hp}− severe gastritis (S), n = 8; total \textit{Hp}−, n = 28; \textit{Hp}+ severe gastritis (S), n = 11). **P < .01; one-way ANOVA. (D) qPCR expression of Tlr9 (relative to 18s rRNA) in gastric body tissues from WT mice at 4 months after oral gavage with either broth or \textit{H felis} (\textit{Hp}), n = 6 mice/group. **P < .01; unpaired Student t test. (E and F) Shown are (E) stomach weights and (F) mucosal thicknesses of WT and Tlr9\textsuperscript{-/-} mice at 4 months after oral gavage with either broth or \textit{H felis} (n = 12 mice/group). (G) Representative photomicrographs showing H&E-stained whole slide scans of stomachs. Scale bars: 1 mm. (H) Western blots of gastric body tissue lysates from Tlr9\textsuperscript{-/-} and WT mice at 4 months after oral gavage with either broth or \textit{H felis} with the indicated antibodies. Graphs depict densitometry quantification of the indicated phosphorylated signaling molecules shown in the Western blots (n = 3 lysates/group), and relative expression was determined against the corresponding amount of total protein. *P < .05, **P < .01; one-way ANOVA.}
\end{figure}
has been described in certain cancer types (eg, brain, colon). The complex role of TLR9 in cancer is also evidenced by observations that TLR9 exhibits both tumor-promoting and tumor suppressive activities within a specific cancer type such as glioma. The mechanistic basis for these contrasting pro- and anti-tumorigenic effects of TLR9 remains unclear. However, it is likely to involve differences in the temporal (ie, early versus late stage) expression pattern of TLR9, as well as the cell types (eg, epithelial, immune) in which TLR9 is predominantly expressed, the latter of which is influenced by the highly heterogeneous TME among cancers.

The opposing roles of TLR9 in cancer also extend to contrasting observations on its pro- or anti-inflammatory activities in the pathogenesis of Helicobacter-induced gastritis. For instance, in a 3-week H felis infection mouse model, TLR9 elicited a pro-inflammatory response as evidenced by reduced numbers of infiltrating neutrophils in the gastric mucosa of infected Tlr9/- mice. Importantly, our current study builds on this observation by demonstrating a causal role for TLR9 in promoting chronic H felis-induced gastric pathology, incorporating gastritis and gastric epithelial hyperplasia that are aligned with the initiating stages of H pylori-induced human GC. However, conversely, an anti-inflammatory role for TLR9 has been assigned during early phases of H pylori infection, whereby Tlr9/- mice displayed elevated gastric neutrophil infiltration within 6–8 weeks after H pylori (SS1 and PMS1 strains) infection. Although TLR9-mediated recognition of H pylori DNA is likely to be one mechanism by which Helicobacter species can hijack TLR9-dependent cellular responses in the host, the reason for the contrasting roles reported for TLR9 in Helicobacter-induced inflammatory responses is less clear but may involve differences in study design relating to the genetic backgrounds of mouse strains, variations within the gut microbiota observed among animal facilities, and/or strains of Helicobacter used (eg, H pylori SS1, H pylori PMS1, H felis).

It is also noteworthy to compare our findings on the role of TLR9 in promoting the early initiating stages of GC with those of other TLR family members, among which TLR2 is best characterized for its prominent role in driving the growth of established tumors in later stages of GC. A likely explanation for the differential roles of TLR2 and TLR9 in GC is that TLR2 drives tumorigenesis by directly augmenting proliferation and suppressing apoptosis of the...
Figure 9. Genetic ablation of Tlr9 reduces H felis-induced gastric inflammation. (A-D) Representative photomicrographs showing (A) H&E-stained, (B) CD45-stained, (C) B220-stained, and (D) CD3-stained cross sections under low power (left images) and high power (right images) magnification through the body of stomachs from Tlr9+/− and WT mice at 4 months after oral gavage with either broth or H felis. Also shown are the corresponding graphs depicting (A) the inflammation scores or (B–D) positive cells/high power field (HPF). Scale bars: 200 μm (left images) and 50 μm (right images). n = 6 mice/group. *P < .05, **P < .01, ***P < .001; one-way ANOVA. (E) qPCR expression of representative inflammatory genes (relative to 18s rRNA) in gastric corpus (body) tissues from the stomachs of WT and Tlr9+/− mice at 4 months after oral gavage with either broth or H felis. n = 6 mice/group. *P < .01, **P < .001, ***P < .0001; one-way ANOVA. (F and G) In (F), qPCR expression of H felis flaB (relative to Gapdh), and (G) representative agarose gel of reverse transcription PCR of H felis flaB along with Gapdh, in stomachs from WT and Tlr9+/− mice at 4 months after oral gavage with either broth or H felis. n = 6 mice/group. *P < .01, **P < .001; one-way ANOVA.
with Helicobacter infection. Although the mechanism by which TLR9 is transcriptionally up-regulated in gastric inflammation-associated tumorigenesis is currently unknown, it is likely to involve NF-κB, whose dysregulated activation is a common feature of gastric tumorigenesis and Helicobacter infection. In addition, a single nucleotide polymorphism within the TLR9 promoter (TLR9-12377T/C), which increases TLR9 transcriptional activity in response to NF-κB, is associated with increased risk of H pylori-mediated premalignant changes in the gastric epithelium. These findings are in concordance with our current study, in which we observed elevated Thr9 mRNA levels in early, but not late, stage gp130F/F gastric tumors, which aligned with the high and very low levels of NF-κB activity in early and late stage gastric tumors, respectively.

In conclusion, our study defines a key role for TLR9 in the initiating stage of gastric inflammation-associated tumorigenesis (including that caused by Helicobacter infection), whereby up-regulation of TLR9 promotes the proliferative outgrowth of gastric epithelial cells. In the gp130F/F GC model, TLR9 deficiency led to the selective suppression of early initiation (10-week-old mice), but not later establishment and progression (20-week-old mice), stage of gastric tumorigenesis by transiently impairing the proliferative potential of the gastric epithelium, as well as immune cell infiltration in the TME. These observations aligned with reduced NF-κB (and to a lesser extent, ERK MAPK) activity on TLR9 deficiency in early (but not late) stage gp130F/F tumors, when TLR9 is also significantly up-regulated. Because activation of NF-κB (but not ERK MAPK) also associated with the TLR9-driven proliferative responsiveness of human GC cells, we propose that up-regulation of TLR9 in the gastric epithelium and concomitant preferential activation of NF-κB is an important step in the early stages of gastric tumorigenesis. Interestingly, because NF-κB is also a potent inducer of inflammatory responses, it is possible that TLR9 engages with NF-κB (and potentially other pathways) to also induce early inflammatory responses in the gastric compartment. We also note that in the later establishment and progression stages of gastric tumorigenesis, the chronic inflamed TME overrides the initial TLR9-driven activities on gastric epithelial and immune cells, thus promoting tumor progression independent of TLR9. In this regard, elevated Thr9 mRNA levels in the stroma-enriched non-tumor versus tumor tissues of 24-week-old gp130F/F mice are likely a consequence of the sustained presence of TLR9-expressing immune cell infiltrates in the highly inflamed gastric TME of 24-week-old gp130F/F mice. Moreover, our study raises the intriguing question of the relative contribution of TLR9 expression and activation in gastric epithelial versus immune cells to the pathogenesis of gastric inflammation and carcinogenesis. Although the host gastric epithelium is the first line of defense against H pylori, macrophages are critical facilitators of the early gastric inflammatory response to H pylori, whereby upon their recruitment to the infected gastric mucosa, they subsequently infected by H pylori, leading to their activation, which facilitates the recruitment and activation of additional inflammatory cells (eg, macrophages themselves, neutrophils, dendritic cells). Indeed, our observation that TLR9 is expressed in both gastric epithelial and immune cell-enriched stroma compartments, albeit at markedly reduced levels in the latter, supports the notion that although the tumor-promoting mechanisms of TLR9 are primarily mediated by its direct epithelial cell regulation, other mechanisms, for instance those impacting immune cell function, might also operate. Therefore, future reciprocal bone marrow chimera studies in both gp130F/F and H felis infection models will play a pivotal role in elucidating the relative contribution of TLR9-expressing bone marrow-derived hematopoietic (ie, immune) cells to gastric disease pathogenesis. We also note that our findings pave the way for future studies to investigate the role of the microbiome in triggering TLR9-induced gastric inflammation-associated tumorigenesis, for instance by comparing the extent of gastric tumorigenesis in germ-free gp130F/F versus gp130F/F;Thr9−/− mice, and/or specific pathogen-free gp130F/F versus gp130F/F;Thr9−/− mice treated with broad-spectrum antibiotics to eliminate gastric microbes.

Methods

Human Biopsies

Snap-frozen and formalin-fixed gastric tissue biopsies were collected from GC or GC-free patients enrolled at Monash Medical Centre (Melbourne, Australia) and Xinhua Hospital (Shanghai, China) undergoing surgical resection or upper gastrointestinal endoscopy (Table 1). Patients with a history of taking nonsteroidal anti-inflammatory drugs, proton pump inhibitors, or antibiotics were excluded. Histopathological assessment and H pylori status were determined as before. Full and informed patient consent was obtained, and biopsy collections were approved by the Monash Health Human Research Ethics Committee and Xinhua Hospital Ethics Committee.

Mouse Strains

The gp130F/F and Thr9−/− mice (the latter donated by S. Summers, Monash University, Australia) have been described previously and were used to generate gp130F/F:Thr9−/− mice. All mice were on a mixed 129Sv x C57BL/6 background, and where possible equal numbers of male and female mice were used. Genetically matched and age-matched littermates, including WT controls, were included in all experiments. Mice were housed under specific pathogen-free conditions on a 12-hour light/dark cycle. All animal experiments were approved by the Monash University Monash Medical Centre "B" Animal Ethics Committee.

H felis Infection Model

H felis (strain CS1) was cultured on horse blood agar (Oxoid, Nepean, Canada) and then harvested and cultured in brain heart infusion broth (Oxoid) to yield H felis suspensions for mouse inoculation. WT and Thr9−/− male and female mice aged 4–6 weeks were randomly administered with a single 100 μL aliquot of either control brain heart infusion broth or 2 × 10^7 H felis bacteria by oral gavage and then culled after 4 months.
**RNA Isolation and Gene Expression Analyses**

Total RNA was isolated from snap-frozen human and mouse gastric tissues and cultured human GC cell lines using TRI Reagent Solution (Sigma-Aldrich, St Louis, MO), followed by on-column rNeasy Mini Kit RNA clean-up and DNase treatment (Qiagen, Hilden, Germany). RNA was transcribed using the Transcript High Fidelity cDNA Synthesis Kit (Roche, Basel, Switzerland). qPCR was performed using the 7900HT Fast RT-PCR System (Applied Biosystems, Waltham, MA), and data were acquired and analyzed as before.58 Total RNA and qPCR analyses were performed on laser microdissected mouse gastric tissues as described before.58 Human (h) TLR9 and mouse (m) T9 gene primer sequences are as follows, and for other genes primer sequences are available on request or have been previously published.59,8,11,31,32,57,58: hTLR9 Forward 5'-GTCAGAGTCAAGGTGAAGT-3', hTLR9 Reverse 5'-CTTGTCTCTAAAATGACTC-3'; mTLR9 Forward 5'-ACTGAGACCCCGTGCCTCTA-3', mTLR9 Reverse 5'-AGATTAGTCAGCGGCAAGA-3'; mGapdh Forward 5'-CATGGCCTTCCGTGTTTCCA-3'.

**Protein Expression Analysis**

Immunoblots were performed with antibodies against TLR9 (1:500 dilution) (Abcam), pSer536/pSer565 NF-kB, pThr202/pTyr204-ERK1/2, pSer473-Akt, pTyr705-STAT3, total STAT3, total p65 NF-kB, total ERK1/2, total Akt (each at 1:1000 dilution) (Cell Signaling Technology and Actin (1:1000 dilution) (Sigma-Aldrich). Membranes were analyzed using the Odyssey CLx Imaging System (LiCor, Lincoln, NE), and protein expression was quantified as before.8,11 An ELISA kit to detect tumor necrosis factor α (BD Biosciences) in gastric tissue lysates was used according to manufacturer's instructions.

**Cell Proliferation and Viability Assays**

AGS, NUGC4, MKN28, and gp130βF primary gastric epithelial cells (2 × 10^4) were seeded in triplicate wells in 96-well plates. After 24 hours of serum starvation, cells were treated with either ODN 2006 CpG oligonucleotide (Class B) or ODN 2006 control oligonucleotide (Inovigen, San Diego, CA) for 24 hours (proliferation) or 48 hours (viability). Where indicated, cells were also pretreated for 30 minutes with specific inhibitors against the ERK MAPK (U0126; 0.5 μmol/L; Cell Signaling Technology) and NF-kB (TPCA-1; 10 μmol/L; Selleck Chemicals, Houston, TX) pathways before stimulation with CpG or control oligonucleotides (both at 2 μmol/L). Cell proliferation was assessed with the ClickIT EdU Microplate Assay (Molecular Probes, Eugene, OR) and cell viability by using the MTT assay.8,11

**Human Gastric Cancer Patient Datasets**

Gene expression data and clinical information from TCGA 18 intestinal-type GC cases with paired tumor and adjacent non-tumor tissue (Table 1), as well as 57 intestinal-type GC cases classified into H pylori-negative or -positive (Table 3), were obtained from TCGA data portal (https://portal.gdc.cancer.gov/projects/TCGA-STAD). We used
reads/kilobase of exon model/million mapped reads to quantify TLR9 gene expression levels from RNA sequencing data generated from each GC patient.

The Gastric Cancer Project*08 -- Singapore Patient Cohort (GSE15459) dataset (Table 1) was sourced for TLR9 gene expression profiling and overall survival analyses as described previously.10,23

Statistics

All statistical analyses were performed using GraphPad Prism V8.0.2 (San Diego, CA) software. Data normality was assessed using the Agostino and Pearson omnibus K2 normality test, and the appropriate tests to identify statistical significance (P < .05) between the means of 2 or multiple groups are presented in the relevant figure legends.

All data in figures are expressed as the mean ± standard error of the mean from at least 3 technical replicates. The log-rank test was used to calculate the statistical significance of the difference in survival between 2 groups.

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68:394–424.
2. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol 2006;12:354.
3. Wroblewski LE, Peek RM Jr, Wilson KT. Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev 2010;23:713–739.
4. Castaño-Rodriguez N, Kaakoush NO, Mitchell HM. Pattern-recognition receptors and gastric cancer. Front Immunol 2014;5:336.
5. Chmiela M, Karwowska Z, Goniarcz W, Allushi B, Staczeck P. Host pathogen interactions in Helicobacter pylori related gastric cancer. World J Gastroenterol 2017;23:1521–1540.
6. Neill LA, Golenbock D, Bowie AG. The history of toll-like receptors: redefining innate immunity. Nat Rev Immunol 2013;13:453–460.
7. West AC, Jenkins BJ. Inflammatory and non-inflammatory roles for toll-like receptors in gastrointestinal cancer. Curr Pharm Des 2015;21:2968–2977.
8. Tye H, Kennedy CL, Najdovska M, McLeod L, Mccormack W, Hughes N, Dev A, Sievert W, Ooi CH, Ishikawa TO, Oshima H, Bhathal PS, Parker AE, Oshima M, Tan P, Jenkins BJ. STA3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation. Cancer Cell 2012;22:466–478.
9. Man SM, Jenkins BJ. Context-dependent functions of pattern recognition receptors in cancer. Nat Rev Cancer 2022. https://doi.org/10.1038/s41568-022-00462-5.
10. Castaño-Rodriguez N, Kaakoush NO, Pardo AL, Goh KL, Fock KM, Mitchell HM. Genetic polymorphisms in the toll-like receptor signalling pathway in Helicobacter pylori infection and related gastric cancer. Hum Immunol 2014;75:808–815.
11. West AC, Tang K, Tye H, Yu L, Deng N, Najdovska M, Lin SJ, Balic JJ, Okochi-Takada E, McGuirk P, Keogh B, Mccormack W, Bhathal PS, Reilly M, Oshima M, Ushijima T, Tan P, Jenkins BJ. Identification of a TLR2-regulated gene signature associated with tumor cell growth in gastric cancer. Oncogene 2017;36:5134–5144.
12. Belmont L, Rabbe N, Antoine M, Cathelin D, Guignabert C, Kurie J, Cadranel J, Wislez M. Expression of TLR9 in tumor-infiltrating mononuclear cells enhances angiogenesis and is associated with a worse survival in lung cancer. Int J Cancer 2014;134:765–777.
13. Zambrinis CP, Levine E, Guay S, Avanzi A, Barilla R, Xu Y, Seifert L, Daley D, Greco SH, Deutsch M, Jonnadula S, Torres-Hernandez A, Tippens D, Pushalkar S, Eisenthal A, Saxena D, Ann H, Hajdu C, Engle DD, Tuveson D, Miller G. TLR9 ligatin in pancreatic stellate cells promotes tumorigenesis. J Exp Med 2015;212:2077–2094.
14. Ilvesaro JM, Merrell MA, Li L, Wakchoure S, Graves D, Brooks S, Rahko E, Jukkola-Vuorinen A, Vuopala KS, Harris KW, Selandor KS. Toll-like receptor 9 mediates CpG oligonucleotide-induced cellular invasion. Mol Cancer Res 2008;6:1534–1543.
15. Zhang Y, Wang Q, Ma A, Li Y, Li R, Wang Y. Functional expression of TLR9 in esophageal cancer. Oncol Rep 2014;31:2298–2304.
16. Dai Q, Li XP, Chai L, Long HA, Yang ZH. Polymorphisms of toll-like receptor 9 are associated with nasopharyngeal carcinoma susceptibility. Tumour Biol 2014;35:3247–3253.
17. Wang C, Cao S, Yan Y, Ying Q, Jiang T, Xu K, Wu A. TLR9 expression in glioma tissues correlated to glioma progression and the prognosis of GBM patients. BMC Cancer 2010;10:415.
18. Wang TR, Peng JC, Qiao YQ, Zhu MM, Zhao D, Shen J, Ran ZH. Helicobacter pylori regulates TLR4 and TLR9 during gastric carcinogenesis. Int J Clin Exp Pathol 2014;7:6950–6955.
2122 19. Dajon M, Iribarren K, Cremer I. Toll-like receptor stimulation in cancer: a pro- and anti-tumor double-edged sword. Immunobiology 2017;222:89–100.
2123 20. Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest 2007;117:1184–1194.
2124 21. Varga MG, Piazzuelo MB, Romero-Gallo J, Delgado AG, Suarez G, Whitaker ME, Krishna US, Patel RV, Skaar EP, Wilson KT, Algood HM, Peek RM Jr. TLR9 activation suppresses inflammation in response to Helicobacter pylori infection. Am J Physiol Gastrointest Liver Physiol 2016;311:G852–G858.
2125 22. Otani K, Tanigawa T, Watanabe T, Nadatani Y, Sugawa M, Yamagami H, Shiba M, Watanabe K, Torinaga K, Fujisawa Y, Arakawa T. Toll-like receptor 9 signaling has anti-inflammatory effects on the early phase of Helicobacter pylori-induced gastritis. Biochem Biophys Res Commun 2012;426:342–349.
2126 23. Anderson AE, Worku ML, Khamri W, Bamford KB, Walker MM, Thursz MR. TLR9 polymorphisms determine murine lymphocyte responses to Helicobacter: results from a genome-wide scan. Eur J Immunol 2007;37:1548–1561.
2127 24. Ooi C, Ivanova T, Wu J, Lee M, Tan IB, Tao J, Ward L, Koo JH, Gopalakrishnan V, Zhu Y, Cheng LL, Lee J, Rha SY, Chung HC, Ganesan K, So J, Soo KC, Lim D, Chan WH, Wong BK, Bowtell D, Yeoh KG, Grabsch H, Boussioutas A, Tan P. Oncogenic pathway combinations predict clinical prognosis in gastric cancer. pLoS Genet 2009;5:e1000676.
2128 25. Balic JJ, Garcia MJ, Saad MI, Yu L, West AC, West AJ, Livis T, Bhatnal PS, Gough DJ, Jenkins BJ. Serine-phosphorylated STAT3 promotes tumorigenesis via modulation of RNA polymerase transcriptional activity. Cancer Res 2019;79:5272–5287.
2129 26. Jenkins BJ, Grail D, Nheu T, Najdovska M, Wang B, Patterson LM, Simmons AJ, Bilton RJ, Betts JW, Lau KS, Magness ST, Goldenring JR. Choi E. Heterogeneity and dynamics of active Kras-induced dysplastic lineages from mouse corpus stomach. Nat Commun 2019;10:5549.
2130 27. Poh AR, Dwyer AR, Eissmann MF, Chand AL, Baloyan D, Jenkins BJ, Grail D, Nheu T, Najdovska M, Wang B, Patterson LM, Simmons AJ, Bilton RJ, Betts JW, Lau KS, Magness ST, Goldenring JR. Choi E. Heterogeneity and dynamics of active Kras-induced dysplastic lineages from mouse corpus stomach. Nat Commun 2019;10:5549.
2131 28. Topley N, Baumann H, Judd LM, Giraud AS, Waring P, Inglese M, McLoughlin RM, Jones SA, Topley N, Baumann H, Judd LM, Giraud AS, Waring P, Inglese M, McLoughlin RM, Jones SA. Helicobacter pylori infection and resolution of gastritis by adoptive transfer of splenocytes in mice. Infect Immun 2001;69:1025–1031.
2132 29. Sigal M, Rothenberg ME, Logan CY, Lee JY, Honaker RW, Cooper RW, Passarelli B, Camorlinga M, Bouley DM, Alvarez G, Nusse R, Torres J, Amieva MR. Helicobacter pylori activates and expands Lgr5(+) stem cells through direct colonization of the gastric glands. Gastroenterology 2015;148:1392–1404 e21.
2133 30. Lennerz JK, Kim SH, Oates EL, Huh WJ, Doherty JM, Tian X, Bredemeyer AJ, Goldenring JR, Lauwers GY, Shin YK, Mills JC. The transcription factor MiST1 is a novel human gastric chief cell marker whose expression is lost in metaplasia, dysplasia, and carcinoma. Am J Pathol 2010;177:1514–1533.
2134 31. Choi E, Hendley AM, Bailey JM, Leach SD, Goldenring JR. Expression of activated Ras in gastric chief cells of mice leads to the full spectrum of metaplastic lineage transitions. Gastroenterology 2016;150:918–930 e13.
2135 32. Min J, Vega PN, Engevik AC, Williams JA, Yang Q, Patterson LM, Simmons AJ, Bilton RJ, Betts JW, Lau KS, Magness ST, Goldenring JR, Choi E. Heterogeneity and dynamics of active Kras-induced dysplastic lineages from mouse corpus stomach. Nat Commun 2019;10:5549.
2136 33. Tsugawa H, Kato C, Mori H, Matsuoka J, Kameyama K, Saya H, Hatakeyama M, Suematsu M, Suzuki H. Cancer stem-cell marker CD44v9-positive cells arise from Helicobacter pylori-infected CAPZA1-overexpressing cells. Cell Mol Gastroenterol Hepatol 2019;8:319–334.
2137 34. Eaton KA, Mefford M. Cure of Helicobacter pylori infection and resolution of gastritis by adoptive transfer of splenocytes in mice. Infect Immun 2001;69:1025–1031.
2138 35. Li JK, Balic JJ, Yu L, Jenkins BJ. TLR agonists as adjuvants for cancer vaccines. Adv Exp Med Biol 2017;1024:195–212.
2139 36. Kim IY, Yan X, Tohme S, Ahmed A, Cordon-Cardo C, Shantha Kumara HM, Kim SK, Whelan RL. CpG ODN, toll like receptor (TLR)-9 agonist, inhibits metastatic colon adenocarcinoma in a murine hepatic tumor model. J Surg Res 2012;174:284–290.
2140 37. El Andaloussi A, Sonabend AM, Han Y, Lesniak MS. Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors. Glia 2006;54:526–535.
2141 38. Herrmann A, Cherryholmes G, Schroeder A, Phallen J, Alizadeh D, Xin H, Wang T, Lee H, Lahtz C, Swiderski P, Armstrong B, Kowolik C, Gallia GL, Lim M, Brown C, Badie B, Forman S, Kortylewski M, Jove R, Yu H. TLR9 is critical for glioma stem cell maintenance and targeting. Cancer Res 2014;74:5218–5228.
2142 39. Kadu RR, Ballhorn W, Voland P, Eisenacher K, Mages J, Rad LR, Funst RL, Lang R, Wagner H, Schmid RM, Bauer S, Prinz C, Kischning CJ, Krug A. Extracellular and intracellular pattern recognition receptors cooperate in the recognition of Helicobacter pylori. Gastroenterology 2023;106:2247–2257.
2143 40. Alvarez-Arellano L, Cortés-Reynosa P, Sánchez-Zuazo N, Salazar E, Torres J, Maldonado-Bernal C, TLR9 and NF-κB are partially involved in activation of human neutrophils by Helicobacter pylori and its purified DNA. pLoS One 2014;9:e101342.
2144 41. Ishii Y, Shibata W, Sugimori M, Kaneta Y, Kanno M, Sato T, Sue S, Kameta E, Kaneko H, Irie K, Sasaki T, Kondo M, Maeda S. Activation of signal transduction and anti-inflammatory mechanisms of human neutrophils by Helicobacter pylori. J Pathol 2010;225:2257–2266.
2145 42. Sokolova O, Naumann M. NF-κB signaling in innate immunity against Helicobacter pylori infection. Semin Immunol 2017;29:63–73.
2146 43. Ying L, Ferrero RL. Role of NOD1 and ALPK1/TIFA signaling in innate immunity against Helicobacter pylori infection. Immunol Rev 2017;280:190–204.
2147 44. Honaker RW, Cooper RL, Passarelli B, Camorlinga M, Bouley DM, Alvarez G, Nusse R, Torres J, Amieva MR. Helicobacter pylori activates and expands Lgr5(+) stem cells through direct colonization of the gastric glands. Gastroenterology 2015;148:1392–1404 e21.
infection. Curr Top Microbiol Immunol 2019; 421:159–177.

44. Ng MT, Va’t Hof R, Crockett JC, Hope ME, Berry S, Thomson J, McLean MH, McColl KE, El-Omar EM, Hold GL. Increase in NF-kappaB binding affinity of the variant C allele of the toll-like receptor 9 -1237T/C polymorphism is associated with Helicobacter pylori-induced gastric disease. Infect Immun 2010; 78:1345–1352.

45. Algood HM, Gallo-Romero J, Wilson KT, Peek RM Jr, Cover TL. Host response to Helicobacter pylori infection before initiation of the adaptive immune response. FEMS Immunol Med Microbiol 2007;51:577–586.

46. Kaparakis M, Walduck AK, Price JD, Pedersen JS, Van Rooijen N, Pearse MJ, Wijburg OL, Strugnell RA. Macrophages are mediators of gastritis in acute Helicobacter pylori infection in C57BL/6 mice. Infect Immun 2008; 76:2235–2239.

47. Quiding-Jarbrink M, Raghavan S, Sundquist M. Enhanced M1 macrophage polarization in human helicobacter pylori-associated atrophic gastritis and in vaccinated mice. pLoS One 2010;5:e15018.

48. Lehours P, Ferrero RL. Review: Helicobacter— inflammation, immunology, and vaccines. Helicobacter 2019;24(Suppl 1):e12644.

49. Kennedy CL, Najdovska M, Jones GW, McLeod L, Hughes NR, Allison C, Ooi CH, Tan P, Ferrero RL, Jones SA, Dev A, Sievert W, Bhathal PS, Jenkins BJ. The molecular pathogenesis of STAT3-driven gastric tumourigenesis in mice is independent of IL-17. J Pathol 2011;225:255–264.

50. Ernst M, Najdovska M, Grail D, Lundgren-May T, Buchert M, Tye H, Matthews VB, Armes J, Bhathal PS, Hughes NR, Marcusson EG, Karras JG, Na S, Sedgwick JD, Hertzog PJ, Jenkins BJ. STAT3 and STAT1 mediate IL-11–dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. J Clin Invest 2008;118:1727–1738.

51. Hemmi H, Takeuchi O, Kawai T, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Hughes NR, Marcusson EG, Karras JG, Na S, Takeda K, Akira S. A toll-like receptor recognizes bacterial DNA. Nature 2000;408:740–745.

52. Chownerawong M, Ferrand J, Chaudhry HM, Higgins C, Tran LS, Lim SS, Walker MM, Bhathal PS, Dev A, Moore GT, Sievert W, Jenkins BJ, Elios MM, Philpott DJ, Kufer TA, Ferrero RL. Innate immune molecule NLRC5 protects mice from Helicobacter-induced formation of gastric lymphoid tissue. Gastroenterology 2020; 159:189–182 e8.

53. Ferrero RL, Wilson JE, Sutton P. Mouse models of Helicobacter-induced gastric cancer: use of cocarcinogens. Methods Mol Biol 2012;921:157–173.

54. Balic JJ, Saad MI, Dawson R, West AJ, McLeod L, West AC, Costa K, Deswaarte V, Dev A, Sievert W, Gough DJ, Bhathal PS, Ferrero RL, Jenkins BJ. Constitutive STAT3 serine phosphorylation promotes Helicobacter-mediated gastric disease. Am J Pathol 2020;190:1256–1270.

55. Velin D, Favre L, Bernasconi E, Bachmann D, Pythoud C, Saji E, Bouzourene H, Michetti P. Interleukin-17 is a critical mediator of vaccine-induced reduction of Helicobacter infection in the mouse model. Gastroenterology 2009;136:2237–2246.

56. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 2012; 9:671–675.

57. Dawson R, Deswaert V, West AC, Tang K, West AJ, Balic JJ, Gearing LJ, Saad MI, Yu L, Wu Y, Bhathal PS, Kumar B, Chakraborti JT, Zavros Y, Oshima H, Klinman DM, Oshima M, Tan P, Jenkins BJ. STAT3-mediated upregulation of the A2M DNA sensor links innate immunity with cell migration to promote epithelial tumourigenesis. Gut 2021.

58. Deswaerte V, Nguyen P, West A, Browning AF, Yu L, Ruwanpura SM, Balic J, Livis T, Girard C, Preaued A, Oshima H, Fung KY, Tye H, Najdovska M, Ernst M, Oshima M, Gabay C, Putoczki T, Jenkins BJ. Inflammation-adaptor ASC suppresses apoptosis of gastric cancer cells by an IL18-mediated inflammation-independent mechanism. Cancer Res 2018;78:1293–1307.

Received February 7, 2021. Accepted June 6, 2022.

Correspondence
Address correspondence to: Brendan J. Jenkins, Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Monash University, 27–31 Wright Street, Clayton, Victoria 3168, Australia. e-mail: Brendan.Jenkins@hudson.org.au; fax: XXX.

CRediT Authorship Contributions
Ke Tang (Formal analysis; Supporting; Investigation; Lead; Methodology; Lead)
Louise McLeod (Data curation; Equal)
Thalita Livis (Formal analysis; Supporting; Investigation; Supporting; Methodology; Supporting)
Alison West (Formal analysis; Supporting; Investigation; Supporting; Methodology; Supporting)
Ruby Dawson (Data curation; Equal)
Liang Yu (Investigation; Supporting; Methodology; Supporting)
Jesse Balic (Investigation; Supporting; Methodology; Supporting)
Michelle Chownerawong (Investigation; Supporting; Methodology; Supporting)
Georgie Wray-mccann (Investigation; Supporting; Methodology; Supporting)
Hiroko Oshima (Data curation; Equal)
Masanobu Oshima (Data curation; Equal)
Virginie Deswaerte (Investigation; Supporting; Methodology; Supporting)
Richard Ferrero (Funding acquisition; Supporting; Methodology; Supporting; Resources; Supporting; Supervision; Supporting; Writing—review & editing; Supporting)
Brendan Jenkins (Conceptualization; Lead; Data curation; Lead; Formal analysis; Lead; Funding acquisition; Lead; Project administration; Lead; Resources; Lead; Supervision; Lead; Validation; Lead; Writing—original draft; Lead)

Conflicts of interest
The authors disclose no conflicts.

Funding
Supported by research grants from the National Health and Medical Research Council (NHMRC) of Australia awarded to B.J. Jenkins (APP1139371) and R.L. Ferrero (APP1107930), as well as the Operational Infrastructure Support Program by the Victorian Government of Australia. K. Tang was supported by Monash Graduate and Monash International Postgraduate Research Scholarships. R.L. Ferrero (APP1079904) and B.J. Jenkins (APP1154279) are supported by NHMRC Senior Medical Research Fellowships.